In recent years, an increasing number of innovative therapies such as interferon and cytokine-related molecules have been applied to the clinical treatment from lab researches, and have realized respective industrialization transcending the academic world. Among the world's top 10 best-selling drugs, 7 are biological ones and 5 are those related to cytokines or cytokine receptors. The global sales volume of cytokine-targeted antibodies and fusion proteins is about USD 65 billion, ranking the first among all biotechnological products and being the fastest growing pharmaceutical segment in the world. However, contrasting with the increasingly thriving external environment of new drugs development, the lack of supporting resources like talent, capital, policies, R&D hardware and core technologies restrict further breakthroughs in new drugs in China.
In the face of opportunities and challenges in the development of cutting-edge innovative therapy, "2019 BioTianfu Tumor Immunology Industry-University-Research Integrated Innovation Summit Forum & the 20th Interferon and Cytokines Academic Annual Conference" will discuss the latest development and future trend of interferon and cytokine-related molecules. Meanwhile, this Forum will hold the Innovation Forum for Scientific and Technological Talents in Colleges and Universities and the Matchmaking Symposium for the Transfer and Transformation of Scientific Research Achievements & Supporting Personnel, so as to promote China's leapfrog development of the fields including interferon, cytokine-related molecules and tumor immune regulation molecules in an all-round and multi-angle way.
Organizations
Guided by
Chengdu High-tech Industrial Development Zone Management Committee (continue to increase...)
Sponsor
Interferon and Cytokine Professional Committee, Chinese Society for Microbiology
Organizers
CDHT Investment Group Biomedicine Industrial Park Management Co., Ltd., Hui Hui Yao Ka
Co-organizers
Jiangsu Biological Technology Association, Shanghai Society of Biotechnology, Chinese Biopharmaceutical Association (CBA), Chengdu Two-Winning Enterprise Management Co., Ltd.[LYY1] , Chengdu Boao Innovative Pharmaceutical Technology Co., Ltd., Novoprotein Scientific Inc., Shanghai Medicilon Inc., Suzhou Daojin Co., Ltd., Jian River Pharmaceuticals, dMed Biopharmaceutical Co., Ltd. (keep increasing...)
Honorary Presidents
Academician Liu Xinyuan, Academician Hou Yunde, Academician Jiao Binghua
Executive President
Ni Jian
Summit Overview
Date
12月6日--8日（周五--周日）
December 6-8, 2019 (Friday-Sunday)
Venue
OCG International Center, CDHT, Chengdu, China
Participants
About 500 participants including experts, scholars and entrepreneurs from all over the world
Conference Agenda
December 07, 2019
China
Special Topic: Exchange in Sichuan — Basic Research and Industrialization of Interferon and Cytokine-related Molecules
09:00-09:20
Opening Ceremony
09:00-09:10
Speech by the sponsor
Ni Jian, Chairman of the Specialized Committee of Interferon and Cytokines
09:10-09:20
Policy Interpretation and Development Planning for the Biomedical Industry in Chengdu
The Management Committee of Chengdu Hi- tech Industrial Development Zone
09:20-09:50
Reporting Speech
Hou Yunde, Academician of Chinese Academy of Engineering & Winner of 2017 State Preeminent Science and Technology Award
09:50-10:20
Reporting Speech
Liu Xinyuan (to be confirmed), Academician of Chinese Academy of Sciences
10:20-10:50
Reporting Speech
Wei Yuquan, Academician of Chinese Academy of Sciences
10:50-11:20
LIVER CANCER RESEARCH: MECHANISM, DIAGNOSIS AND THERAPY
GEN-SHENG FENG PH.D THE UNIVERSITY OF CALIFORNIA SAN DIEGO
11:20-11:50
Preclinical Studies of Protein/Antibody Drugs and IND Declaration Strategies
Chen Chunlin, CEO of Shanghai Medicilon Inc.
11:50-12:20
The Overview of Drug Registration in the EU
Lin Jie, CEO of the EU Branch of dMed Biopharmaceutical Co., Ltd.
12:20-13:00
Lunch & Break
13:00-13:30
Reporting Speech
Fu Xinyuan, President of Generos Biomedical Technology (Hangzhou) Co, Ltd.
13:30-14:00
Innovative Protein Analysis Technology Improves the Quality Control of Macromolecular Biological Drugs
Han Aiming, General Manager of ProteinSimple Biotechnology Co., Ltd. in Greater China
14:00-14:30
The Quality Control of Biotechnological Drugs and Improvement of Recombinant Cytokine Standards in the New Pharmacopoeia
Rao Chunming, Director of the Recombinant Drugs Office, the Biological Products Assay Institute under the National Institutes for Food and Drug Control
14:30-15:00
Key Points in Non-clinical Evaluation Studies of Immune Checkpoint Inhibitors
Cen Xiaobo, CEO & Director of WestChina-Frontier PharmaTech Co., Ltd. (National Chengdu New Drug Safety Evaluation Center)
15:00-15:10
Tea Break and Group Photos of Guests
15:10-15:40
The Research on Targeting Imaging of Immune Cells Marked with Nanoparticles and Collaborative Treatment of Tumors
Cui Daxiang, Vice President of the Shanghai Research Center for Translational Medicine of Shanghai Jiao Tong University
15:40-16:10
Theme Report
Yang Shuwei, Founder of Guangzhou Funeng Gene Co., Ltd.
16:10-16:50
The Application of Cytokines in Tumor Immunotherapy
Tao Weikang, Deputy General Manager of Jiangsu Hengrui Medicine Co., Ltd.
16:50-17:50
Round-table Discussion: The Evaluation of Cytokine Industry in the Development of Precision Therapy
Guests:
Zhang Dan, Executive President of Fountain Medical Development Ltd.
Zhu Huaxing, CEO of Novoprotein Scientific Inc.
Zhang Qinghua, Founder of Shanghai H·wayen Biotechnologies Co., Ltd.
Zhang Xumu, Lifetime Chair Professor & Head of Department of Chemistry of the Southern University of Science and Technology
Xing Tongjing, Director of the Central Laboratory under the Jiangsu Taizhou People's Hospital
18:30-21:00
Banquet: The Night in Chengdu
December 08, 2019; OCG International Center, CDHT, Chengdu, China
OCG International Center, CDHT, Chengdu, China
Sub-forum I: Perfect Pair - The Integration and Transformation of Production, Education and Research
09:00-09:25
T CELL-BASED THERAPIES FOR CANCERS.
XIAO-NING XU PROFESSOR IMPERIAL COLLEGE LONDON
09:25-09:50
The Trend and Modes of Innovative Ecological Construction in China's Biomedical Parks
Rui Guozhong, Vice-President of China Association of Technology Entrepreneurs & Secretary-General of China Biomedical Park Development Alliance
09:55-10:15
Advances in Therapeutic Vaccines and Discovery of Neoantigens
Chen Ping, President of Chinese Biopharmaceutical Association (CBA)
10:15-10:40
Interferon and Cytokine Product Evaluation Strategies and Focuses
Yan Fengying, Deputy General Manager of Tianjin Institute of Pharmaceutical Research
10:40-11:05
Reporting Speech
Li Guochun, Partner of bioVenture
11:05-11:30
Macromolecular Clinical Trial Program and Project Management
Zhang Shengjun, Vice President of Suzhou Zhaoyan Pharmaceutical Technology Co., Ltd.
11:30-11:55
The R&D Status and Trend of Drugs Targeting at Cytokines in the Era of Tumor Immunotherapy
Guo Lei, Director of the Advisory Service Department of Pharmacodia (Beijing) Co., Ltd.
11:55-12:25
Round-table Discussion: The Integration of Industry, University and Research in the Field of Cytokines
Host: Xiang Junjian, Professor of Ji'nan University
12:30-13:30
Lunch & Break
December 08, 2019; OCG International Center, CDHT, Chengdu, China
OCG International Center, CDHT, Chengdu, China
Sub-forum II: Potential Talents - Talent Training and on-the-Job Personnel
Learning & Innovation Forum
09:00-09:25
The Interpretation of Chengdu Talent Introduction Policies
Sichuan Provincial Human Resources and Social Security Department
09:25-09:50
CYTOKINE TNFSF15 ACTIONS ON TUMOR VASCULAR AND LYMPHATIC SYSTEMS
Li Luyuan, Director of State Key Laboratory of Medicinal Chemistry & Biology under the Nankai University
09:50-10:15
Reporting Speech
Fan Yichao, Investment Director of Wisdo Mont Asset Management
10:15-10:40
PK-PD Research Strategies of Innovative Macromolecular Biological Drugs
Cheng Yuanguo, CSO of Shanghai Yinuosi Bio-Technology Co., Ltd.
10:40-11:05
The Clinical Research Status and Challenges of Anti-PD-1/PD-l1 Tumor Immunotherapy in China
Cao Lixia, Manager of Project Management of WuXi AppTec Co,. Ltd.
11:05-11:30
The Analysis on the Platform for Transgenic Animals with Humanized Antibody and Its Patents
Ge Liangpeng, General Manager of Chongqing Camab Biotech Ltd.
11:30-12:30
Round-table Discussion: Talent Training and Export Docking
12:30-13:30
Lunch & Break
December 08, 2019; OCG International Center, CDHT, Chengdu, China
OCG International Center, CDHT, Chengdu, China
Sub-forum III: Each Demonstrating His Special Skill: Project Roadshow Forum
13:30-13:50
Award Ceremony
13:50-14:00
Winner's Speech
14:00-18:00
Project Roadshows
Experts of the Jury:
Xiang Junjian, Professor of Ji'nan University
Zhao Baisong, Founder of Hopkins Medicine Research Institute
Zhang Lurong, Scientific Counselor of Fujian Provincial Tumor Hospital & Leading Talent in Fujian Higher Education & Former Professor of the Radiotherapy Department in the Medical College of University of Florida, the US
Kuang Jiao, Executive Director of Clinical Development of Antengene Corporation
Wang Haining, Founder of Longmen Capital
Fan Xionglin, Professor & Deputy Head of Tongji Medical College, Huazhong University of Science & Technology
Xia Hongxi, President & General Manager of Yeli Biotechnology (Shanghai) Co., Ltd.
Highlights of the Forum
1. Gathering of masters: Several academicians of Chinese Academy of Sciences and Chinese Academy of Engineering, more than one hundred enterprise executives and professors from research institutes gather together
2. Dream palace in the field of cytokine: The Forum focuses on global knowledge in frontier areas and provides a high-level platform for exchanges and cooperation
3. Coverage of policies to human resources: The most authoritative interpretation of the policies related to talents and the most professional planning for career development are available here
4. Integration of government, industry, university and research: The Forum pools 300+ projects of excellent achievements transformation of medical colleges and universities nationwide, smoothing the "last mile" in integrating industry, university and research
5. Throughout all processes of industry, university and research: The Forum realizes the transformation of university and college achievements through policy support and project investment, promoting the transformation of achievements in full speed.
6. Full media coverage: It connects 50,000+ people working in high-end pharmaceutical industries; releases real-time conference news through 300+ industry WeChat groups ; and gains the strong support of 100+ pharmaceutical media partners
Strategic Media Support
(arranged in alphabetical order)
Conference Expenses
Charged by: Chengdu Boao Innovative Medical Technology Co., Ltd.
Bank of Deposit: Chengdu Yongfeng Sub-branch, Industrial and Commercial Bank of China
Account No.: 4402 9220 0910 0183 289
Contact us
Conference Liaison: Zhao Chunyu
Tel.: 15281172375 (also the WeChat account)
E-mail: 18000558050@163.com
Conference Liaison: Feng Li
Tel.: 18613208073 (also the WeChat account)
E-mail: FENGLI@BIOTIANFU.COM
Investment Attraction Liaison: Huang Jing
Tel.: 18000558050 (also the WeChat account)
E-mail: 18000558050@163.com
Media Liaison: LISA-GAO
Tel.: 18883179194 (also the WeChat account)
E-mail: 18000558050@163.com
Traffic Guide
Conference Location: F4, Building A, OCG International Center, No.158, Tianfu 4th Street, CDHZ, Chengdu (Can be located in Suining Bank)
Traffic Guide
4th Tianfu Street East, 4th Tianfu Street East, 4th Tianfu Street-Yizhou Avenue Intersection, 4th Tianfu Street-Tianfu Avenue Intersection, Yizhou Avenue-4th Tianfu Street Intersection, Tianfu Avenue-4th Tianfu Street Intersection, Tianfu Avenue-4th Tianfu Street Intersection, Yizhou Avenue-4th Tianfu Street Intersection, Tianfu Avenue-2nd Tianhua Road Intersection, Metro 3rd Tianfu Street, 4th Tianfu Street-Yizhou Avenue Intersection, 5th Tianfu Street, Tianfu Avenue 3rd Tianfu Street Intersection, Yizhou Avenue 3rd Tianfu Street Intersection, Yizhou Avenue 5th Tianfu Street Intersection and Tianfu Avenue 3rd Tianfu Street.
Buses near the OCG International Center:
Recommendation: Tianfu 4th Street East (Westward): Buses No. 124, No. 131, No. 171A, No.171B, No. 236, No.503A, No. G32 and No. G91
Chengdu Shuangliu International Airport - Building A of OCG International Center;
Short time - (start) Terminal 2 of Shuangliu International Airport of Metro Line 10 - Taipingyuan, transferring Metro Line 7 (Outer Ring) - South Railway Station, transferring Metro Line 1 - Tianfu 3rd Street, Exit B (end), 14 stops in total, about 6 yuan, walking for 1.3 km, about 1 hour and 1 minute.
Less walk - (start) Terminal 2 of Shuangliu International Airport of Metro Line 10 - Taipingyuan, transferring Metro Line 7 (Outer Ring) - South Railway Station, Exit E - Walk for 137 m to South Railway Station Transportation Hub, taking Bus No. 236 - Tianfu 4th Street East (end), 22 stops in total, about 7 yuan, walking for 531 m, about 1 hour and 15 minutes.
How much does it cost to take a taxi to the OCG International Center?
The staring fare of taxi in Chengdu is 8.0 yuan for less than or equal to 2 km. For the distance more than 2 km, 1.9 yuan/km is charged, without fuel surcharge. This is only for reference.
Registration Method
1. Scan the QR Code below to get the admission ticket worth 1,000 yuan for free of charge.
[LYY1]标红企业名自译
Park WeiChart